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Circulating tumor DNA (ctDNA) has emerged as a potential new biomar-
ker with diagnostic, predictive, and prognostic applications for various
solid tumor types. Before beginning large prospective clinical trials to prove
the added value of utilizing ctDNA in clinical practice, it is essential to
investigate the effects of various preanalytical conditions on the quality of
cell-free DNA (cfDNA) in general and of ctDNA in particular in order to
optimize and standardize these conditions. Whole blood samples were col-
lected from patients with metastatic cancer bearing a known somatic vari-
ant. The following preanalytical conditions were investigated: (a) different
time intervals to plasma isolation (1, 24, and 96 h) and (b) different preser-
vatives in blood collection tubes (EDTA, CellSave, and BCT). The quality
of cfDNA/ctDNA was assessed by DNA quantification, digital polymerase
chain reaction (dPCR) for somatic variant detection and a b-actin fragmen-
tation assay for DNA contamination from lysed leukocytes. In 11 (69%)
of our 16 patients, we were able to detect the known somatic variant in
ctDNA. We observed a time-dependent increase in cfDNA concentrations
in EDTA tubes, which was positively correlated with an increase in wild-
type copy numbers and large DNA fragments (> 420 bp). Using different
preservatives did not affect somatic variant detection ability, but did stabi-
lize cfDNA concentrations over time. Variant allele frequency was affected
by fluctuations in cfDNA concentration only in EDTA tubes at 96 h. Both
CellSave and BCT tubes ensured optimal ctDNA quality in plasma pro-
cessed within 96 h after blood collection for downstream somatic variant
detection by dPCR.
1. Introduction
Circulating tumor DNA (ctDNA) has emerged as a
potential new biomarker in the field of oncology. The
quantification and characterization of ctDNA in
plasma creates numerous potential applications,
including detection of minimal residual disease, early
evaluation of treatment response, and stratification for
targeted therapy according to specific genetic changes
(Bidard et al., 2014; Dawson et al., 2013; Diaz and
Bardelli, 2014; Diehl et al., 2008; Forshew et al., 2012;
Murtaza et al., 2013; Shinozaki et al., 2007).
Abbreviations
cfDNA, cell-free DNA; ctDNA, circulating tumor DNA; dPCR, digital polymerase chain reaction; EDTA, ethylenediaminetetraacetic acid; IQR,
interquartile ranges; VAF, variant allele frequency.
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The application of ctDNA-based diagnostic tests
into the clinic still faces several technical difficulties.
The biggest hurdle might be the detection limit:
ctDNA may comprise < 1.0% of the total cell-free
DNA (cfDNA), making detection of the tumor-specific
fraction challenging (Diehl et al., 2005, 2008; Holdhoff
et al., 2009). The majority of cfDNA is derived from
apoptotic tissue and hematological cells which release
their DNA in the circulation (Elshimali et al., 2013;
Jahr et al., 2001). Thus, the absolute quantity of
cfDNA (‘the background’) determines our ability to
detect ctDNA, and quantification of the tumor-specific
variant frequency depends both on the abundance of
ctDNA molecules and on the total amount of cfDNA.
One of the most important factors impacting the total
amount of cfDNA is the time to plasma processing
after blood collection, which increases the release of
wild-type DNA from lysed hematological cells present
in the blood collection tube (Norton et al., 2013; Xue
et al., 2009). To avoid this, plasma needs to be sepa-
rated from the blood sample within hours after the
blood draw, but the maximum time frame to do so,
remains to be revealed.
Due to logistical and practical reasons, it is often
not possible to process and store blood samples imme-
diately after blood withdrawal to ensure optimal
ctDNA quality; especially in the context of large multi-
center prospective clinical trials, which are essential to
definitely establish ctDNA as a clinically relevant new
biomarker, there is a need for standardization of pre-
analytical conditions that allow longer processing time
of blood samples. To overcome this problem, special-
ized ‘cell-stabilizing’ blood collection tubes have been
developed. These tubes should not only minimize con-
tamination by wild-type DNA from lysed hematologi-
cal cells in the blood tube, but also preserve the
quality of ctDNA for reliable downstream analyses.
Until today, a number of studies have tested the dif-
ferent available blood collection tubes to optimally
preserve cfDNA/ctDNA (Norton et al., 2013; Roth-
well et al., 2016; Sherwood et al., 2016; Toro et al.,
2015). They all demonstrate a time-dependent increase
in cfDNA concentrations in ethylenediaminetetraacetic
acid (EDTA) tubes, while cfDNA concentrations
remained stable in both BCT and CellSave tubes. Toro
et al. (2015) included the PAXgene blood DNA tube
in their study, but this tube did not improve the results
obtained with EDTA tubes. Yet, even though preser-
vation methods have been compared (Kang et al.,
2016), thorough direct comparisons between BCT and
CellSave tubes at clinically relevant time frames are
missing. We set out to compare the available preserva-
tives to allow easier implementation of ctDNA-based
tests into larger clinical trials where processing of sam-
ples within 1 h presents a major logistical challenge.
The purpose of this study was to investigate the effect
on the quality of cfDNA in general and of ctDNA in
particular in patients with metastatic cancer under the
following preanalytical conditions: (a) different time
intervals to plasma isolation (1, 24, and 96 h) and (b)
different types of preservative in the blood collection
tubes (EDTA, CellSave, and BCT tubes). To this pur-
pose, the amount of cfDNA isolated from plasma was
quantitated, its size determined, and the fraction of
ctDNA determined.
2. Materials and methods
2.1. Patient characteristics and somatic variant
status of tumor
Between October 2015 and January 2016, cancer
patients within the Erasmus MC Cancer Institute in
Rotterdam, the Netherlands, were invited to contribute
blood samples for this study by their treating physi-
cian. Patients were included if they had metastatic dis-
ease, were not currently receiving systemic treatment,
and if a validated digital polymerase chain reaction
(dPCR) assay (TaqMan SNP genotyping assays,
ThermoFisher Scientific, Waltham, MA USA; see also
section 2.4) was available for the known somatic vari-
ant in their primary and/or metastatic lesion. Somatic
variant status and variant allele frequency (VAF) in
tissue had been assessed as part of the standard of care
by the molecular diagnostics laboratory of the depart-
ment of pathology in the Rotterdam region by either
Sanger sequencing (patient #10 and #16), SNaPshot
analysis (patient #05), or NGS analysis (all other
patients). The DNA input for these analyses ranged
from 0.48 to 10 ng. The calculation of VAF was made
through NGS analysis by calculating the coverage of
the variant nucleotide relative to the total coverage on
that position. For tissue samples analyzed by Sanger
sequencing, the VAF was calculated by determining
the ratio between the variant peak and the wild-type
peak. All patients provided written informed consent,
and the institutional review board approved the proto-
cols (Erasmus MC ID MEC 15-616).
2.2. Preanalytical conditions
After obtaining written informed consent, 9 9 10 mL
of blood samples was collected within a single blood
draw (see Fig. S1). Matched blood samples were col-
lected in sterile 3 9 10 mL K2EDTA tubes (ETDA)
(BD Vacutainer, Becton Dickinson, Franklin Lanes,
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NJ, USA), 3 9 10 mL Cell-Free DNATM BCT (BCT)
(Streck Inc., Omaha, NE, USA), and 3 9 10 mL Cell-
Save Preservative tubes (Janssen Diagnostics, Raritan,
NJ, USA) according to the manufacturer’s instruc-
tions. The blood samples from one of each type of
tube (EDTA, BCT, and CellSave) were processed for
plasma isolation at three different time points: within
1 h, at 24 h and at 96 h after blood draw (see
Fig. S1). Plasma was isolated using two sequential cen-
trifugation steps: (a) 1711 g for 10 min at room tem-
perature and (b) 12 000 g for 10 min at room
temperature. Plasma was stored at 80 °C in 1 mL
aliquots immediately after centrifugation until further
processing.
2.3. cfDNA isolation and quantification
For cfDNA isolation, plasma samples were thawed at
4 °C and 3 mL of plasma per sample was used.
cfDNA was isolated using the QIAamp Circulating
Nucleic Acid kit (QIAGEN, Venlo, Limburg, The
Netherlands) according to the manufacturer’s instruc-
tions. cfDNA was eluted from the QIAGEN Mini
column using 50 lL buffer AVE which was applied
three times to the column to obtain the highest cfDNA
concentration possible. cfDNA was stored at 20 °C.
cfDNA concentrations were quantified using the
Quant-iT dsDNA high-sensitivity assay (Invitrogen,
Life Technologies, Carlsbad, CA, USA) according to
the manufacturer’s instructions, and the Qubit fluo-
rometer (Invitrogen) was used as readout.
2.4. Digital PCR TaqMan SNP genotyping and
b-actin fragmentation assay
Cell-free DNA samples were thawed at room tempera-
ture. Validated TaqMan SNP genotyping assays
(ThermoFisher Scientific) were used for somatic vari-
ant and wild-type detection according to the manufac-
turer’s instructions (see Table S1). Accordingly, the
limit of detection of this assay is 0.1% (ThermoFisher
Scientific, 2016). The maximum volume input of
7.8 lL of the final cfDNA eluate was used, unless the
amount of cfDNA in this volume exceeded the maxi-
mal input of 30 ng cfDNA, and then 30 ng cfDNA
was used. Depending on the obtained cfDNA concen-
tration after plasma isolation, at least 2.57 ng cfDNA
was analyzed, leading to a limit of detection of 0.78%.
The TaqMan b-actin fragmentation assay was
based on the assay developed by Norton et al. (2013)
to detect a small (136-bp) and long (420-bp) b-actin
fragments. We adapted the assay so that both frag-
ments were measured within a single experiment using
the reported primers, but different probes for each
fragment (see Table S2). For the b-actin fragmentation
assay, a standardized input of 2 ng cfDNA was used
to minimize the change of having multiple DNA frag-
ments in one well.
All dPCRs were performed with the QuantStudio
3D dPCR System (ThermoFisher Scientific) according
to the manufacturer’s protocol. In short, dPCR reac-
tion mix was prepared containing 8.7 lL QuantStudio
3D dPCR Master Mix v2, 0.44 lL Taqman primer/
probe mix, up to 7.8 lL of cfDNA, and the total vol-
ume was completed with PCR-grade H2O to a final
volume of 17.4 lL. Using the QuantStudio 3D dPCR
Chip Loader, samples were partitioned on a 20 000-
well QuantStudio 3D dPCR Chip v2 followed by a
PCR on a ProFlex 2x Flat PCR System with the fol-
lowing program: 10 min at 96 °C, 409 cycles of 2 min
at 60 °C, followed by 30 s at 98 °C, 2 min at 60 °C,
and pause at 10 °C. The dPCR data were then
acquired with the QuantStudio 3D dPCR Instrument,
and the data were analyzed with the QuantStudio 3D
Analysis Suite by one technician (JH) to account for
interobserver variability.
2.5. Statistical analysis
The Wilcoxon signed rank test was used to compare
the difference between matched 1-h and 24-h samples
relative to the difference between matched 1-h and
96-h samples. The Friedman test was used to test the
order of the three 1-h samples. To correct for multiple
testing, we adjusted the P value for significance using
the Bonferroni correction. Significance was thus
defined as P < 0.008 (0.05/6). Correlations were tested
by Spearman’s rank correlation coefficient.
Cell-free DNA concentrations determined by the
Quant-iT dsDNA high-sensitivity assay were corrected
for the plasma input and were converted from
ng per mL plasma to copies per mL plasma by taking
into consideration that 3.3 pg of human DNA con-
tains one copy of a single gene. cfDNA concentrations
were then log-transformed.
To correct for differences in plasma input used for
cfDNA isolation and for differences in elution volume
after cfDNA isolation, we expressed dPCR results as
variant/wild-type copies per mL plasma. To calculate
variant/wild-type copies per mL plasma, the following
equation as described by Lo et al. (1998) was used:
C ¼ Q ðVDNAÞ=VPCRÞ  ð1=VextÞ;
where C is variant/wild-type copies per mL plasma; Q
is the total number of variant/wild-type copies deter-
mined by dPCR; VDNA is the total volume of cfDNA
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obtained after cfDNA isolation; VPCR is the volume of
cfDNA solution used for the dPCR reaction; and Vext
is the volume of plasma used for cfDNA isolation.
To calculate VAF, we divided the variant copies per
mL plasma by the sum of variant and wild-type copies
per mL plasma.
All statistical analyses were performed using STATA
version 14.1 (StataCorp LLC, College Station, TX,
USA). All figures were plotted using R version 3.2.3 (R
Foundation for Statistical Computing, Vienna, Austria).
3. Results
3.1. Somatic variant detection rate in ctDNA of
recruited patients
A total of 16 patients were included who all met the
set criteria to investigate the effect of different preana-
lytical conditions on the quality of ctDNA. Somatic
variant status of the primary and/or metastatic lesion
had been previously assessed, either by targeted next-
generation sequencing (13 of 16 patients), by SNaP-
shot analysis (one of 16 patients), or by traditional
Sanger sequencing (two of 16 patients). Table 1 lists
the origin of the primary tumor, the site and number
of metastases, and the VAF in the tumor tissue. Using
the specific TaqMan SNP genotyping assay (see
Table S1), we were able to detect in 11 (69%) of our
16 patients the known somatic variant in ctDNA iso-
lated within 1 h from EDTA tubes. This corresponds
to the detection of 13 (68%) of 19 of the total number
of somatic variants tested as some patients had multi-
ple known somatic variants.
3.2. Temporal effect of storage in EDTA tubes on
cfDNA quality
To investigate the effect of different time intervals
from blood withdrawal to plasma isolation on cfDNA
quality, we measured cfDNA concentration isolated
from plasma collected in EDTA tubes. We observed a
significant increase in cfDNA concentrations in sam-
ples isolated after 96 h compared to samples isolated
within 1 h (P < 0.001; see Fig. 1 and Fig. S2). This
increase in cfDNA concentration was significantly pos-
itively correlated with an increase in wild-type copy
numbers (rho = 0.85; P < 0.001; see Fig. 2A). If a
somatic variant was detected in the 1-h sample, the
somatic variant could also be detected in 24 and 96-h
samples. We also observed a significant positive corre-
lation between variant copy numbers and cfDNA con-
centration, although this was less strong (rho = 0.42;
P < 0.001; see Fig. 2B).
To investigate whether the increase in cfDNA con-
centrations and wild-type copy numbers was due to
the release of intact DNA from lysed leukocytes, we
used the b-actin fragmentation assay (see Fig. 3A). In
all preanalytical conditions, we detected low amounts
of large fragments. We observed significantly more
large fragments in samples from 96 h than in samples
from 1 h (420 bp P < 0.001; 2000 bp P < 0.001; see
Fig. 3C). There was also a small but significant
increase in fragmented DNA in samples from 96 h
compared to samples from 1 h (136 bp P = 0.002;
Fig. 3B).
3.3. The interaction between different
preservatives and plasma isolation time intervals
and cfDNA quality
Next, we studied the effect of different preservatives in
blood collection tubes on cfDNA quality. We com-
pared cfDNA concentrations isolated from plasma col-
lected in EDTA, BCT, and CellSave tubes processed
within 1 h. Cell-free DNA concentrations were similar
in all blood collection tubes (see Fig. 1 and Fig. S2).
We also did not observe any differences in the DNA
fragment size distribution with the b-actin fragmenta-
tion assay for the different tubes at 1 h (see Fig. 3B).
In order to investigate whether the used preserva-
tives in BCT and CellSave tubes could prevent the
time-dependent increase in cfDNA concentration
observed in EDTA tubes, we measured cfDNA con-
centrations in samples isolated after 24 h and 96 h
after blood withdrawal. We observed stable cfDNA
concentrations in all 24-h and 96-h samples compared
to their matched 1-h samples (see Fig. 1 and Fig. S2).
Also, we did not observe any differences in the DNA
size distribution with the b-actin fragmentation assay
for the matched time intervals for both tube types (see
Fig. 3B).
3.4. The interaction between different
preservatives and plasma isolation time intervals
on somatic variant detection in ctDNA
To study the effect of time-dependent increase in
cfDNA concentrations and wild-type copy numbers on
somatic variant detection, we analyzed VAF in the dif-
ferent preanalytical conditions compared to their
matched 1-h sample. If a somatic variant was detected
in the EDTA 1-h sample, the somatic variant could
also be detected in all BCT and CellSave samples.
There was no correlation between the VAF in tumor
tissue and the VAF in plasma (see Fig. S3). There was
a significant decrease in VAFs in samples from EDTA
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96 h (P = 0.003; see Fig. 4), which was not observed
for the other preanalytical conditions. Because all
tubes were drawn within a single blood draw, we
expected, in contrast to VAF, that all tubes within
each patient contain similar amounts of variant copy
numbers. Indeed, variant copy numbers appeared lar-
gely similar between tubes and in all tubes compared
to their matched 1-h sample (see Fig. 5 and Fig. S4).
4. Discussion and conclusions
The purpose of this study was to investigate the effects
of various preanalytical conditions on the quality of
cfDNA in general and of ctDNA in particular. The
main aim was to investigate whether BCT and Cell-
Save tubes processed within 96 h after blood withdra-
wal into plasma were suitable for downstream analyses
of ctDNA.
Patients were recruited with a high prior probability
to harbor ctDNA in their plasma, that is, patients
with metastatic disease without current anticancer
treatment. In 69% of our patients, we were able to
detect the known somatic variant from tissue in
ctDNA and this corresponds to the detection of 68%
of all tested somatic variants. In two of six missed
somatic variants, the somatic variant status in tissue
was assessed > 3 years ago. It may be possible that
other cancer subclones have emerged, resulting in
undetectable somatic variants in ctDNA. Unfortu-
nately, in these cases, more recent information on
somatic variant status was not available. Detection of
somatic variants in plasma may also be influenced by
the site and extent of metastases, which is exemplified
by patient #05. This patient had a widespread pattern
of metastases with corresponding high levels of
cfDNA and high levels of variant copy numbers in
plasma. However, due to our heterogeneous cohort,
this relationship could not be tested statistically for
the other patients.
Fig. 1. cfDNA concentrations for different preanalytical conditions.
Boxes [interquartile ranges (IQR)] and whiskers (1.5 9 IQR) are
shown together with the median (black horizontal line) of the log
cfDNA concentrations in copies per mL plasma of 16 patients for
the different preanalytical conditions. Outliers are displayed as
black dots. The Wilcoxon signed rank test was used to compare
the difference between matched 1-h and 24-h samples relative to
the difference between matched 1-h and 96-h samples.
*P < 0.001.
Fig. 2. Correlation between wild-type or variant copy numbers and cfDNA concentration. The log number of wild-type copies (A) or variant
copies (B) in copies per mL plasma on the x-axis is plotted against the log cfDNA concentrations in copies per mL plasma on the y-axis.
Data points correspond to single sample measurements from each time interval and each type of preservative. Correlations were tested by
Spearman’s rank correlation coefficient. *P < 0.001. Five patients with undetectable variant copy numbers in ctDNA are removed from plot
B.
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The clinical utility and potential importance of our
methods is evidenced by our findings in patient #02,
who was thought to have metastases from his pancre-
atic carcinoma (first primary cancer) harboring a
KRAS mutation. However, we could only detect
BRAF and PIK3CA mutations in his ctDNA, highly
suggestive that the metastases were originating from
the patients’ colorectal cancer (second primary cancer),
which can have important implications for his disease
management.
The formation of small DNA fragments (180–
200 bp lengths) is a biochemical hallmark of apopto-
sis, whereas during cell lysis or necrosis intact genomic
DNA and thus much larger DNA fragments (50–
300 kbp) remain (Bortner et al., 1995). Through an
increase in wild-type copy numbers and mainly intact
DNA fragments, we were able to demonstrate that the
time-dependent increase in cfDNA concentration in
EDTA tubes indeed originates from leukocyte lysis. In
addition, we observed low levels of intact DNA frag-
ments in all preanalytical conditions, indicating a
background level of leukocyte lysis. Both Norton et al.
(2013) and Rothwell et al. (2016) observed a similar
increase in cfDNA concentrations in samples collected
in EDTA tubes. In both BCT and CellSave tubes,
cfDNA concentrations, wild-type copy numbers, and
b-actin fragment sizes remained stable up to 96 h,
indicating that the preservative in these tubes does not
adversely affect cfDNA quality. Interestingly, there
was also a significant increase in fragmented DNA in
Fig. 3. b-Actin fragmentation assay for different preanalytical conditions. (A) Principle of b-actin fragmentation assay. dPCR wells containing
only 136-bp signal are indicative of fragmented DNA (fragments < 200 bp), whereas the 420-bp primer set will only bind to intact DNA
(> 420 bp). When a large intact DNA fragment (> 2000 bp) is present in one of the wells, both primer sets can bind, resulting in a mixed
signal. In theory, this can also occur when a small (< 200 bp) and large (> 420 bp) DNA fragment is present together in one well.(B) Results
of b-actin fragmentation assay. Boxes [interquartile ranges (IQR)] and whiskers (1.5 9 IQR) are shown together with the median (black
horizontal line) of the number of b-actin copies for the different preanalytical conditions. Outliers are displayed as black points. The Wilcoxon
signed rank test was used to compare the difference between matched 1-h and 24-h samples relative to the difference between matched
1-h and 96-h samples for the different fragment sizes. *P = 0.002; **P < 0.001.
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samples from EDTA 96 h, which might be attributed
to nucleases remaining active.
As we only used dPCR for downstream analysis of
ctDNA, we cannot rule out the possibility that the
used preservatives in BCT and CellSave tubes could
potentially damage the cfDNA and thus affect other
downstream analyses. Rothwell et al. (2016) assessed
the number of single nucleotide variants through
whole-genome sequencing of cfDNA isolated from
plasma collected in CellSave tubes. They did not
observe introduction of DNA errors. Thus, the preser-
vative used in CellSave tubes does not seem to influ-
ence cfDNA downstream analysis using NGS.
Despite the contamination with intact cfDNA, we
were still able to detect all somatic variants in ctDNA
from EDTA 96-h samples, in those samples where we
were able to detect a somatic variant in the EDTA 1-h
samples. These data suggest that stored samples which
have not been processed optimally for ctDNA analysis
can still be used to determine the presence of somatic
Fig. 5. Variant copy numbers of 11 patients for different preanalytical conditions. Data points correspond to variant copy numbers for each
individual patient and assay. The Wilcoxon signed rank test was used to compare the difference between matched 1-h and 24-h samples
relative to the difference between matched 1-h and 96-h samples.
Fig. 4. VAF of 11 patients for different preanalytical conditions. Data points correspond to VAF for each individual patient and assay. The
Wilcoxon signed rank test was used to compare the difference between matched 1-h and 24-h samples relative to the difference between
matched 1-h and 96-h samples. *P = 0.003.
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variants in ctDNA. As a consequence of increased
cfDNA concentrations and correlated wild-type copy
numbers, we did observe a significant decrease in VAF
in the EDTA 96-h samples. With respect to ctDNA
applications for treatment response evaluation, this
could result in serious misinterpretations of VAFs.
However, variant copy numbers remained stable in all
tubes and might thus be a more accurate outcome
measure to evaluate treatment response in patients
with cancer. Further investigation is needed to deter-
mine the interassay variability regarding the range of
variant copy numbers and VAFs we observed among
the different tubes.
The results in this study indicate that EDTA tubes
processed at 96 h after blood withdrawal are not suit-
able for blood collection for subsequent cfDNA/ctDNA
analysis as the time-dependent increase in cfDNA con-
centration, resulting from leukocyte lysis, significantly
affects VAF. In patient samples with low variant copy
numbers, this increase in cfDNA concentration may
cause variant copies to fall below the limit of detection
of the dPCR assay and thus may lead to false-negative
results. Both BCT and CellSave tubes preserve cfDNA/
ctDNA quality equally well up to 96 h and the used
preservatives did not affect downstream cfDNA/ctDNA
analyses by dPCR. Variant copy numbers and VAFs
also remained stable in these tubes.
Therefore, we recommend for all future clinical
studies, in which flexibility regarding the processing of
blood samples is needed, to isolate plasma from blood
collected in either BCT or CellSave tubes within 96 h.
This will make large multicenter trials using a central
processing facility feasible, and will lead to optimal
quality of ctDNA for research and diagnostics.
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